Literature DB >> 12353713

Herpes simplex virus infection in a hyper-IgE patient: appearance of unusual mass lesions.

Klilah Hershko1, Alon Y Hershko, Vera Leibovici, Karen Meir, Arieh Ingber.   

Abstract

A 7-year-old girl presented with large soft masses rising from the nostril and from behind the ear. She had previously been diagnosed as suffering from hyper-IgE syndrome. The presence of herpes simplex virus infection within these lesions was confirmed by biopsy and immunohistochemical studies. The mass lesions did not respond to antibacterial therapy with cefazolin, but improved promptly under antiviral therapy with acyclovir. Immunological studies revealed a mild decrease in the CD4 cell population. Based on our results and on the relevant literature we propose an immunological mechanism for this unique manifestation of herpes simplex virus infection in hyper-IgE syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353713     DOI: 10.1080/00015550260132514

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

Review 1.  The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.

Authors:  Aleksandra Szczawinska-Poplonyk; Zdzislawa Kycler; Barbara Pietrucha; Edyta Heropolitanska-Pliszka; Anna Breborowicz; Karolina Gerreth
Journal:  Orphanet J Rare Dis       Date:  2011-11-15       Impact factor: 4.123

Review 2.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

3.  Herpes Simplex Virus and Human Papillomavirus Coinfections in Hyperimmunoglobulin E Syndrome Presenting as a Conjunctival Mass Lesion.

Authors:  Mitra Akbari; Ramin Elmi
Journal:  Case Rep Med       Date:  2017-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.